Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…Abstract Number: 471 • 2014 ACR/ARHP Annual Meeting
Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan
Background/Purpose: Many evidences including clinical trials of biologics lead us earlier and more aggressive treatment strategy for patients with rheumatoid arthritis (RA). It is stated…Abstract Number: 2447 • 2014 ACR/ARHP Annual Meeting
The Role of TET3-Mediated DNA Demethylation By Pro-Inflammatory Cytokines in Rheumatoid Arthritis
Background/Purpose In the pathogenesis of Rheumatoid arthritis (RA) RA fibroblast-like synoviocytes (RA FLS) exhibit a unique aggressive phenotype that contributes to the cytokine milieu and…Abstract Number: 1145 • 2014 ACR/ARHP Annual Meeting
Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
Background/Purpose: For rheumatoid arthritis (RA) patients (pts) with inadequate response to a TNF inhibitor (TNFi), limited evidence exists from observational studies and indirect comparisons of…Abstract Number: 465 • 2014 ACR/ARHP Annual Meeting
18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
Background/Purpose: Post-marketing surveillance is an important part of monitoring adverse events (AEs) following the approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor…Abstract Number: 2355 • 2014 ACR/ARHP Annual Meeting
Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro
Background/Purpose Phosphodiesterase 4 (PDE4) inhibitors have clear immunoregulatory effects in laboratory studies, and the clinical application of this class of drug in the field of…Abstract Number: 1031 • 2014 ACR/ARHP Annual Meeting
Induction of Pro-Apoptotic Noxa Expression By Ursolic Acid Sensitizes Rheumatoid Arthritis Synovial Fibroblasts to Apoptosis: A Role of Mir-181a
Background/Purpose: In rheumatoid arthritis (RA), the paucity of pro-apoptotic protein expression may significantly contribute to the resistance of synovial fibroblasts (FLS) to apoptosis. In the…Abstract Number: 452 • 2014 ACR/ARHP Annual Meeting
The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis
Background/Purpose The majority of patients with established Rheumatoid arthritis (RA) have autoantibodies against the Fc of IgG (Rheumatoid factors-RhF) and to citrullinated protein antigens (ACPAs).…Abstract Number: 2356 • 2014 ACR/ARHP Annual Meeting
Toluenesulfonylamido-Chalcone, 4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC) Suppresses Inflammatory Response and Joint Destruction in an Experimental Arthritic Mice and Fibroblast-like Synoviocytes
Background/Purpose TSAHC, a toluenesulfonylamido-chalcone, 4-(p-toluenesulfonylamido)-4-hydroxychalcone is a compound to block proliferation and metastatic potential of cancer cells. Fibroblast-like synoviocytes of rheumatoid arthritis (RA-FLS) have inflammatory…Abstract Number: 940 • 2014 ACR/ARHP Annual Meeting
Reducing Therapy in Rheumatoid Arthritis Patients in Ongoing Remission
Background/Purpose: Due to improved therapeutic management a steadily increasing number of rheumatoid arthritis (RA) patients reach stable remission of disease. Data on withdrawal of medication…Abstract Number: 347 • 2014 ACR/ARHP Annual Meeting
Salt Aggravates Arthritis By Th17 Polarization
Background/Purpose Sodium chloride (NaCl) recently has been shown to drive autoimmune diseases through the induction of pathogenic interleukin 17-producing T helper (Th17) cells. This study…Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…Abstract Number: 886 • 2014 ACR/ARHP Annual Meeting
Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status?
Background/Purpose: Disease remission is the goal of treat-to-target initiatives in rheumatoid arthritis (RA). There are multiple indices to measure disease activity and remission status including…Abstract Number: 324 • 2014 ACR/ARHP Annual Meeting
Regulation of TNF-α-Mediated Activation of Rheumatoid Synovial Fibroblasts By Transcription Factor Snail
Background/Purpose: Transcription factor Snail plays active roles in various biological functions and is involved in many disease states. We hypothesized that this molecule regulates TNF-α-mediated…
- « Previous Page
- 1
- …
- 176
- 177
- 178
- 179
- 180
- …
- 188
- Next Page »